Novartis AG
Polyomavirus neutralizing antibodies
Last updated:
Abstract:
The present disclosure is directed to anti-VP1 antibodies, antibody fragments, and their uses for the reducing the likelihood or treatment of polyoma virus infection.
Status:
Grant
Type:
Utility
Filling date:
8 Sep 2016
Issue date:
22 Oct 2019